Cargando…
Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI
Background: The first goal of the study was to analyse the antibody titre 21 days after the first dose of the BNT162b2 vaccine in a group of 252 healthcare workers (HCW). The second goal was to analyse how the antibody titre changes in correlation with age, gender and body mass index (BMI). Methods:...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310011/ https://www.ncbi.nlm.nih.gov/pubmed/34206312 http://dx.doi.org/10.3390/vaccines9070685 |
_version_ | 1783728658074042368 |
---|---|
author | Pellini, Raul Venuti, Aldo Pimpinelli, Fulvia Abril, Elva Blandino, Giovanni Campo, Flaminia Conti, Laura De Virgilio, Armando De Marco, Federico Di Domenico, Enea Gino Di Bella, Ornella Di Martino, Simona Ensoli, Fabrizio Giannarelli, Diana Mandoj, Chiara Manciocco, Valentina Marchesi, Paolo Mazzola, Francesco Moretto, Silvia Petruzzi, Gerardo Petrone, Fabrizio Pichi, Barbara Pontone, Martina Zocchi, Jacopo Vidiri, Antonello Vujovic, Branka Piaggio, Giulia Morrone, Aldo Ciliberto, Gennaro |
author_facet | Pellini, Raul Venuti, Aldo Pimpinelli, Fulvia Abril, Elva Blandino, Giovanni Campo, Flaminia Conti, Laura De Virgilio, Armando De Marco, Federico Di Domenico, Enea Gino Di Bella, Ornella Di Martino, Simona Ensoli, Fabrizio Giannarelli, Diana Mandoj, Chiara Manciocco, Valentina Marchesi, Paolo Mazzola, Francesco Moretto, Silvia Petruzzi, Gerardo Petrone, Fabrizio Pichi, Barbara Pontone, Martina Zocchi, Jacopo Vidiri, Antonello Vujovic, Branka Piaggio, Giulia Morrone, Aldo Ciliberto, Gennaro |
author_sort | Pellini, Raul |
collection | PubMed |
description | Background: The first goal of the study was to analyse the antibody titre 21 days after the first dose of the BNT162b2 vaccine in a group of 252 healthcare workers (HCW). The second goal was to analyse how the antibody titre changes in correlation with age, gender and body mass index (BMI). Methods: Participants had a nasopharyngeal swab for SARS-CoV-2 and were assessed for the presence of SARS-CoV-2 antibodies at baseline and 21 days after the BNT162b2 priming dose. Results: First dose of BNT162b2 activated immune responses in 98% of the participants. Five HWC had no increase in antibody titre 21 days after the first dose. Antibody titre was greater in young (<38 years) vs. older participants (<38 vs. 47–56 p = 0.002; <38 vs. >56 p = 0.001). Higher antibody levels were detected in underweight vs. pre-obesity group (p = 0.026) and in normal-weight vs. pre-obesity group (p = 0.007). This association was confirmed after adjusting for age (p = 0.0001) and gender (p = 0.00001). Conclusions: Our study demonstrates that a single dose of BNT162b2 activates the immune response, and being young and normal-weight correlate positively with this response. Larger specifically designed clinical trials are needed to validate these results. |
format | Online Article Text |
id | pubmed-8310011 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83100112021-07-25 Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI Pellini, Raul Venuti, Aldo Pimpinelli, Fulvia Abril, Elva Blandino, Giovanni Campo, Flaminia Conti, Laura De Virgilio, Armando De Marco, Federico Di Domenico, Enea Gino Di Bella, Ornella Di Martino, Simona Ensoli, Fabrizio Giannarelli, Diana Mandoj, Chiara Manciocco, Valentina Marchesi, Paolo Mazzola, Francesco Moretto, Silvia Petruzzi, Gerardo Petrone, Fabrizio Pichi, Barbara Pontone, Martina Zocchi, Jacopo Vidiri, Antonello Vujovic, Branka Piaggio, Giulia Morrone, Aldo Ciliberto, Gennaro Vaccines (Basel) Brief Report Background: The first goal of the study was to analyse the antibody titre 21 days after the first dose of the BNT162b2 vaccine in a group of 252 healthcare workers (HCW). The second goal was to analyse how the antibody titre changes in correlation with age, gender and body mass index (BMI). Methods: Participants had a nasopharyngeal swab for SARS-CoV-2 and were assessed for the presence of SARS-CoV-2 antibodies at baseline and 21 days after the BNT162b2 priming dose. Results: First dose of BNT162b2 activated immune responses in 98% of the participants. Five HWC had no increase in antibody titre 21 days after the first dose. Antibody titre was greater in young (<38 years) vs. older participants (<38 vs. 47–56 p = 0.002; <38 vs. >56 p = 0.001). Higher antibody levels were detected in underweight vs. pre-obesity group (p = 0.026) and in normal-weight vs. pre-obesity group (p = 0.007). This association was confirmed after adjusting for age (p = 0.0001) and gender (p = 0.00001). Conclusions: Our study demonstrates that a single dose of BNT162b2 activates the immune response, and being young and normal-weight correlate positively with this response. Larger specifically designed clinical trials are needed to validate these results. MDPI 2021-06-22 /pmc/articles/PMC8310011/ /pubmed/34206312 http://dx.doi.org/10.3390/vaccines9070685 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Pellini, Raul Venuti, Aldo Pimpinelli, Fulvia Abril, Elva Blandino, Giovanni Campo, Flaminia Conti, Laura De Virgilio, Armando De Marco, Federico Di Domenico, Enea Gino Di Bella, Ornella Di Martino, Simona Ensoli, Fabrizio Giannarelli, Diana Mandoj, Chiara Manciocco, Valentina Marchesi, Paolo Mazzola, Francesco Moretto, Silvia Petruzzi, Gerardo Petrone, Fabrizio Pichi, Barbara Pontone, Martina Zocchi, Jacopo Vidiri, Antonello Vujovic, Branka Piaggio, Giulia Morrone, Aldo Ciliberto, Gennaro Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI |
title | Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI |
title_full | Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI |
title_fullStr | Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI |
title_full_unstemmed | Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI |
title_short | Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI |
title_sort | early onset of sars-cov-2 antibodies after first dose of bnt162b2: correlation with age, gender and bmi |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310011/ https://www.ncbi.nlm.nih.gov/pubmed/34206312 http://dx.doi.org/10.3390/vaccines9070685 |
work_keys_str_mv | AT pelliniraul earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT venutialdo earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT pimpinellifulvia earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT abrilelva earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT blandinogiovanni earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT campoflaminia earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT contilaura earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT devirgilioarmando earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT demarcofederico earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT didomenicoeneagino earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT dibellaornella earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT dimartinosimona earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT ensolifabrizio earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT giannarellidiana earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT mandojchiara earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT mancioccovalentina earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT marchesipaolo earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT mazzolafrancesco earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT morettosilvia earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT petruzzigerardo earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT petronefabrizio earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT pichibarbara earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT pontonemartina earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT zocchijacopo earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT vidiriantonello earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT vujovicbranka earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT piaggiogiulia earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT morronealdo earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi AT cilibertogennaro earlyonsetofsarscov2antibodiesafterfirstdoseofbnt162b2correlationwithagegenderandbmi |